CE Marking Received for New HIV-1 and HCV RNA Assays
By LabMedica International staff writers Posted on 24 Jun 2015 |
CE Marking has been received for real-time PCR assays for rapid, quantitative determination in human plasma of Human Immunodeficiency Virus type 1 (HIV-1) and of Hepatitis C Virus (HCV) RNA using the high-performance DxN VERIS system.
DxN VERIS HCV Assay and DxN VERIS HIV-1 Assay are the two latest additions to the growing menu of CE-marked assays for use on the DxN VERIS Molecular Diagnostics System from Beckman Coulter Diagnostics (Brea, CA, USA) allowing for rapid turnaround and a more efficient workflow.
“Beckman Coulter is committed to the ongoing development of assays for DxN VERIS and aims to rapidly expand the DxN VERIS infectious disease portfolio, delivering assays that are both cost- and time-effective,” said Arnd Kaldowski, president, Beckman Coulter Diagnostics. “Tests can be up and running in 10 minutes and, with true single-sample random-access and the shortest turnaround time available, results can be delivered to physicians faster,” said Richard Creager, senior vice president, Molecular Diagnostics Business Unit, and chief scientific officer at Beckman Coulter Diagnostics.
HCV RNA quantification is invaluable for assessment and monitoring of patients undergoing treatment, helping to assess patient compliance, inform response‐guided therapy, and determine sustained viral response (SVR), which corresponds to cure in over 99% of cases. DxN VERIS HCV reliably detects genotypes 1 to 6, and is calibrated to the 4th WHO International Standard for HCV (NIBSC 06/102) using the DxN VERIS technology.
Similarly, quantitative measurement of HIV-1 RNA viral load in plasma plays a vital role in prognosis, management, and treatment monitoring of infected patients. DxN VERIS HIV-1 reliably detects subtypes: Group M (A, C, D, F, G, H); Group N; Group O; CRF AE and CRF AG11, and is traceable to the WHO International Standard for HIV-1 using the DxN VERIS technology.
Short assay run-times (less than 102 minutes for DxN VERIS HCV and less than 87 minutes for DxN VERIS HIV-1) enable faster clinical decision making. Automated sample processing, amplification, and detection enable the user to simply load the sample tube onto the DxN VERIS system, subsequent steps are performed automatically. All DxN VERIS assays are supplied in a unique single-cartridge system, reducing wastage and consumable costs compared to traditional batch-plate systems.
Additional CE marked assays for the system include DxN VERIS CMV Assay (for human Cytomegalovirus in plasma) and DxN VERIS HBV Assay (for Hepatitis B Virus in plasma and serum), with many other assays under development.
Related Links:
Beckman Coulter Diagnostics
DxN VERIS HCV Assay and DxN VERIS HIV-1 Assay are the two latest additions to the growing menu of CE-marked assays for use on the DxN VERIS Molecular Diagnostics System from Beckman Coulter Diagnostics (Brea, CA, USA) allowing for rapid turnaround and a more efficient workflow.
“Beckman Coulter is committed to the ongoing development of assays for DxN VERIS and aims to rapidly expand the DxN VERIS infectious disease portfolio, delivering assays that are both cost- and time-effective,” said Arnd Kaldowski, president, Beckman Coulter Diagnostics. “Tests can be up and running in 10 minutes and, with true single-sample random-access and the shortest turnaround time available, results can be delivered to physicians faster,” said Richard Creager, senior vice president, Molecular Diagnostics Business Unit, and chief scientific officer at Beckman Coulter Diagnostics.
HCV RNA quantification is invaluable for assessment and monitoring of patients undergoing treatment, helping to assess patient compliance, inform response‐guided therapy, and determine sustained viral response (SVR), which corresponds to cure in over 99% of cases. DxN VERIS HCV reliably detects genotypes 1 to 6, and is calibrated to the 4th WHO International Standard for HCV (NIBSC 06/102) using the DxN VERIS technology.
Similarly, quantitative measurement of HIV-1 RNA viral load in plasma plays a vital role in prognosis, management, and treatment monitoring of infected patients. DxN VERIS HIV-1 reliably detects subtypes: Group M (A, C, D, F, G, H); Group N; Group O; CRF AE and CRF AG11, and is traceable to the WHO International Standard for HIV-1 using the DxN VERIS technology.
Short assay run-times (less than 102 minutes for DxN VERIS HCV and less than 87 minutes for DxN VERIS HIV-1) enable faster clinical decision making. Automated sample processing, amplification, and detection enable the user to simply load the sample tube onto the DxN VERIS system, subsequent steps are performed automatically. All DxN VERIS assays are supplied in a unique single-cartridge system, reducing wastage and consumable costs compared to traditional batch-plate systems.
Additional CE marked assays for the system include DxN VERIS CMV Assay (for human Cytomegalovirus in plasma) and DxN VERIS HBV Assay (for Hepatitis B Virus in plasma and serum), with many other assays under development.
Related Links:
Beckman Coulter Diagnostics
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia